Patent expirations and the rise of weight loss medications led to some surprises in the top 20 drugs by global sales.

With more than 30 indications across various cancer types and stages, Merck’s Keytruda was top of the list last year. With $25 billion in global sales, the drug accounted for about 40% of Merck’s total revenue last year. Keytruda's sales are expected to reach $30 billion this year.

Abbvie’s Humira was listed as second in global sales. Humira previously had a nine year run as best selling drug until Pfizer and BioNTech’s Comirnaty knocked it off its perch in 2021.

Click here to read the entire article.